Overview

  • Product name

    Anti-C3d antibody [E28-P]
    See all C3d primary antibodies
  • Description

    Rabbit monoclonal [E28-P] to C3d
  • Host species

    Rabbit
  • Specificity

    This product is specific to C3d, but also C3b and iC3b, since C3d is a product from C3b.

  • Tested applications

    Suitable for: IHC-Pmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human C3d (N terminal).
    Database link: P01024

  • Epitope

    Peptide derived from N-terminal sequence of human C3d complement fragment
  • Positive control

    • Human skin tissue from lesion of the early pemphigus vulgaris (without blister formation)

Properties

  • Form

    Liquid
  • Storage instructions

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage buffer

    pH: 8.00
    Preservative: 0.05% Sodium azide
    Constituents: 0.32% Tris HCl, 2% BSA
  • Concentration information loading...
  • Purity

    Proprietary Purification
  • Purification notes

    This immunoglobulin is the product of one single B-cell line from the crude anti-peptide polyclonal anti-serum. This antibody is purified using a proprietary technique and offers a completely post-translationally modified and properly glycosylated antibody. This offers increased stability.
  • Clonality

    Monoclonal
  • Clone number

    E28-P
  • Isotype

    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab136916 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P 1/100 - 1/200.

Antigen Retrieval method: 

immerse the slide in Tris-EDTA buffer, pH 9.0, and incubate in water bath 40 min at 96-98°C

Target

  • Function

    C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
    Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
  • Tissue specificity

    Plasma.
  • Involvement in disease

    Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:613779]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
    Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
    Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
  • Sequence similarities

    Contains 1 anaphylatoxin-like domain.
    Contains 1 NTR domain.
  • Post-translational
    modifications

    C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localization

    Secreted.
  • Information by UniProt
  • Database links

  • Alternative names

    • Acylation stimulating protein cleavage product antibody
    • AHUS5 antibody
    • ARMD9 antibody
    • ASP antibody
    • C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody
    • C3 antibody
    • c3 complement antibody
    • CO3_HUMAN antibody
    • Complement C3 antibody
    • Complement C3c alpha' chain fragment 2 antibody
    • Complement C3d fragment antibody
    • Complement component 3 antibody
    • Complement component C3 antibody
    • CPAMD1 antibody
    see all

Images

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human skin tissue (4µm) from lesion of the early pemphigus vulgaris (without blister formation) labelling C3d with ab136916 at 1/100 dilution.

References

This product has been referenced in:

  • Wilson HR  et al. Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. Kidney Int 95:655-665 (2019). Read more (PubMed: 30655025) »
  • Kajikawa T  et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev 6:207-215 (2017). IHC-P ; Cynomolgus monkey . Read more (PubMed: 28879212) »
See all 2 Publications for this product

Customer reviews and Q&As

1-3 of 3 Abreviews or Q&A

Application
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample
Human Tissue sections (Liver)
Antigen retrieval step
Heat mediated - Buffer/Enzyme Used: EDTA/TRIS
Specification
Liver
Blocking step
Serum as blocking agent for 30 minute(s) · Concentration: 15% · Temperature: 22°C
Fixative
Formaldehyde

Ali Ahmadi

Verified customer

Submitted Mar 18 2019

Application
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample
Mouse Tissue sections (Diseased mouse kidney | paraffin sections)
Antigen retrieval step
Heat mediated - Buffer/Enzyme Used: Tris-EDTA, pH 9
Permeabilization
No
Specification
Diseased mouse kidney | paraffin sections
Blocking step
Serum as blocking agent for 45 minute(s) · Concentration: 10% · Temperature: 22°C
Fixative
Formaldehyde

Mr. Theodore Kaplan

Verified customer

Submitted Jan 04 2017

Question
Answer

Thank you for contacting us.

The datasheet pdfs can be downloaded from Abcam website.

I hope this information is helpful to you. Please do not hesitate to contact us if you need any more advice or information.

Read More

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up